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Abstract 
A conjugate between a photoactive trans-diazido Pt(IV) pro-drug, trans,trans,trans-
[Pt(N3)2(OH)2(py)2], and folic acid has been synthesized and fully characterized by high 
resolution ESI-MS, NMR and UV-vis spectroscopy. Photoactivation of the Pt-folate conjugate 
with visible light confirmed the generation of cytotoxic Pt(II) species capable of binding to 
guanine nucleobases. Importantly, photoreduction of the Pt(IV) complex triggered the 
photodecomposition of the folate vector into a p-aminobenzoate-containing fragment and 
several pterin derivatives, including 6-formylpterin. Besides exhibiting high dark stability in 
physiological-like conditions, the Pt-folate conjugate was ca. 2x more photocytotoxic towards 
MCF-7 breast cancer cell line than its parent Pt(IV) complex with a high photoselectivity 
index (PI >6.9). The higher photocytotoxicity of the conjugate may be a consequence of its 
higher cellular accumulation and of the generation of a set of different cytotoxic species, 






Folate receptors (FRs), which are involved in the uptake of folic acid (vitamin B9), exist in 
three different isoforms (α, β, and ). Among them, FRα is expressed at very low levels in 
normal tissues, but it is highly up-regulated on the cell surface of a wide variety of cancers, 
including ovarian, kidney, brain, triple-negative breast, colon, lung tumors and head and neck 
carcinomas, making it a well-stablished target for anticancer drug development.1 Owing to 
the frequent overexpression of FRα on human cancers ( 40%), the attachment of folate to 
potent cytotoxic agents represents a promising approach in tumor-targeted chemotherapy.2 
Indeed, folate-based small drug conjugates bind to FRα on cancer cells with high affinity 
resulting in subsequent internalization through receptor-mediated endocytosis, in a the 
process usually as effective as that displayed by folic acid in its free form.  
In recent years, a large variety of chemotherapeutic agents have been conjugated to folic 
acid for active targeted drug delivery, including small organic drugs such as chlorambucil,3 
paclitaxel and derivatives,4 mitomycin C,5 and photosensitizers for application in 
photodynamic therapy.6 One of the most successful folate-small drug conjugates is 
Vintafolide, which delivers a microtubule-destabilizing drug to tumors that overexpress FRα.7 
Vintafolide has shown promising results, both as a single agent, as well as in combination 
with doxorubicin in different clinical trials, being Phase III trials completed in 2014 for the 
treatment of platinum-resistant ovarian cancer.  
Although less deeply investigated, folate conjugates involving metal-based anticancer drugs8 
represent a viable choice for developing novel targeted chemotherapeutic agents operating 
with alternative mechanisms of action compared with organic drugs,9 which would facilitate 
overcoming of inherent or acquired resistance in cancer cells. Among them, Pt(II) and Pt(IV) 
complexes have received great attention owing to the success history of cisplatin and its two 
FDA-approved analogues in the clinical treatment of cancer. One of the first examples of a 
folate-platinum conjugate was reported by Gibson and co-workers who developed long-
circulating PEGylated carboplatin analogues with improved cell permeation abilities by 
conjugating the platinum moiety to folate-targeted PEG carriers.10 Another interesting 
approach to delivering platinum drugs to cancer cells overexpressing FRα was described by 
Lippard and collaborators who took advantage of the two axial positions of Pt(IV) complexes 
to attach them simultaneously to folate and to a delivery system based on a single-wall 
carbon nanotube.11  
Photoactivatable metallodrugs have also demonstrated great potential in photoactivated 
chemotherapy (PACT).12 Diazidodihydroxido Pt(IV) pro-drugs, such as trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (1, Fig. 1), are particularly interesting for improved treatment of cancer 
due to their high stability, low toxicity in the dark, potent photocytotoxicity upon irradiation 
with visible light, and novel mechanisms of action.13 In addition, derivatization of the two 
detachable axial ligands in Pt(IV) complexes offers the possibility to modulate or improve 
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their physicochemical and pharmacological properties such as aqueous solubility, cellular 
uptake and target specificity.14 In this context, we have conjugated Pt(IV) pro-drug 1 to small 
peptides targeting different integrin receptors (αvβ3/αvβ5 or α6) that are overexpressed in 
various cancer cells.15 Complex 1 has also been attached to drug delivery upconversion-
luminescent nanoparticles,16 hydrogels,17 and block copolymer micelles18 for triggering 
activation with longer wavelengths and improving selectivity. 
 
 
Fig. 1 Structure of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1), trans,trans,trans-
[Pt(N3)2(OH)(succ)(py)2] (2), and the schematic representation of the Pt–folate conjugate (3). 
 
Based on these antecedents, herein we report the conjugation of Pt(IV) pro-drug 1 to folic 
acid via its monosuccinate derivative (2, Fig. 1), and investigation of the photoactivation, 
photocytoxicity and cellular accumulation of the resulting Pt-folate conjugate (3). As 
previously found with conjugates involving photoactivatable metallodrugs and targeting 
vectors based on receptor-binding peptides,15,19 the selectivity of the Pt-folate conjugate 
towards cancer cells is controlled at two levels. First, the conjugate will be internalized only in 
cancer cells overexpressing FR, and second, the release of cytotoxic Pt(II) species from the 
Pt(IV) pro-drug will take place only at the tumor irradiation site. As shown in Fig. 1, a 
polyethylene glycol (PEG) spacer was introduced between the Pt(IV) complex and folate to 
increase hydrophilicity and biocompatibility, as well as to separate both moieties in the 
conjugate, the latter being an important issue to maintain recognition by FR. Besides 
increasing water solubility, PEG spacers are known to minimize aggregation and non-specific 
uptake of the resulting conjugates by cells.7 In addition, derivatization of folic acid through the 
 carboxyl group is known not to alter significantly binding affinity for FR, whereas the 
corresponding -carboxyl-linked conjugates are not readily recognized.2b,11 
First, we synthesized a suitable folic acid derivative (4) incorporating a short PEG spacer and 
a primary amino function to facilitate conjugation with complex 2 via the formation of an 
amide bond (Scheme 1). Compound 4 was synthesized in two steps by reaction of the N-
hydroxysuccinimidyl ester of folic acid and N-Boc-4,7,10-trioxa-1,13-tridecanediamine 
followed by acidic TFA treatment to remove the Boc group.11 Then, complex 2 was attached 
to the amino-containing folate derivative by using a strong activator (HATU) in the presence 
of DIPEA in dry DMF for 2 h at RT under an Ar atmosphere and protected from light. The 
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expected Pt-folate conjugate (3) was obtained as a pale yellow solid (32 % yield) after 
purification by reversed-phase HPLC and lyophilization (Fig. S1, ESI†).  
 
 
Scheme 1. Synthesis of Pt-folate conjugate (3). 
 
Conjugate 3 was characterized by high-resolution ESI mass spectrometry, 1H and 13C NMR 
and UV-vis spectroscopy. An m/z value consistent with the calculated value of the charged 
species ([M−H]− and ([M−2H]2−) and with the expected isotopic mass distribution pattern of Pt 
was obtained (Fig. S2, ESI†). In addition, the assignment of the 1H NMR spectra of 3 in 
DMSO-d6 confirmed the covalent attachment of the Pt(IV) complex to folic acid. As shown in 
Fig. 2, the three expected signals of the pyridine ligands in the platinum complex were 
observed at 8.80, 8.27 and 7.82 ppm. In addition, all the diagnostic signals from the three 
components of folate backbone were clearly identified in the aromatic region of the 1H NMR 
spectra (Fig. 2): pterin (a singlet at 8.64 ppm corresponding to proton 7 of the heterocycle), 
p-aminobenzoate (two doublets at 7.64 and 6.63 ppm with J = 8.6 Hz) and glutamate (the 
free -carboxyl group at 11.46 ppm as a broad singlet), together with three signals 
attributable to amide bonds in the Pt-folate conjugate. The UV-vis spectrum of conjugate 3 in 
PBS buffer was essentially the sum of those of the two fragments. On the one hand, both the 
N3 → Pt(IV) LMCT transition of the metal complex and the π-π* electronic transitions of the 
pterin and p-aminobenzoate moieties of folic acid contribute to the broad absorption band 
around 290 nm (Fig. 2). On the other hand, the absorption band in the spectral range 300–
400 nm can be assigned to n-π* electronic transitions in folic acid.20 As expected, 1H NMR 
analysis indicated that Pt-folate conjugate 3 was obtained as mixture of two constitutional 
isomers resulting from the attachment of the PEG linker in compound 4 to both the  and  
carboxyl groups of folic acid, with the -carboxyl-linked derivative drawn in Scheme 1 being 
the major one (ca. 90%). These results are in good agreement with literature reports of other 
folate derivatives since the less hindered  carboxyl group of folic acid reacts typically faster 
to give the  regioisomer.6 The mixture of  and  regioisomers of Pt-folate conjugate 3, 
without further separation, was used in photoactivation and biological studies. In addition, it is 
5 
 
important to note that conjugate 3 was found to be completely stable after incubation for 24 h 
at 310 K in the dark in physiological-like conditions (Fig. S5, ESI†). 
 
Fig. 2 Characterization of Pt-folate conjugate 3. 1H NMR spectra in DMSO-d6 showing the 
region between 6 and 12 ppm (top) and comparison of the UV-vis spectra of complex 1, folic 
acid and conjugate 3 in PBS buffer at 298 K (bottom). *This doublet corresponds to the p-
aminobenzoate moiety of folic acid in the  regioisomer of the conjugate. 
 
Photoactivation of Pt-folate conjugate 3 was investigated in the presence of guanosine 5’-
monophosphate (5’-GMP), since guanine nucleobases in DNA are known to be one of the 
main targets for Pt(II) photoproducts. Irradiation was performed with blue (420 nm) and green 
light (505 nm) in H2O at 37 oC, and the course of the photoactivation process was monitored 
by reversed-phase HPLC-MS. As shown in Fig. 3, irradiation with blue light led to the 
complete disappearance of conjugate 3 and to the formation of the expected photolysis 
products (Scheme 2, pathway A) according to ESI-MS characterization: succinate-folate (5), 
photoreleased Pt(II) complex (6) and the Pt(II)-GMP adduct, trans-[Pt(N3)(5’-GMP)(py)2]+ (7) 
(GMP is considered neutral in all the formulae), which parallels the behavior previously 
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observed for the parent complex 1 and its peptide conjugates.15 In addition, HPLC-MS 
analysis revealed the presence of compound 8 and several pterin derivatives, including 6-
formylpterin (9), whose formation can be explained through the cleavage of the bond 
between the p-aminobenzoate-containing fragment and the pterin ring system in folate 
(Scheme 2, pathway B). To our surprise, cleavage of this bond also occurred at the level of 
the parent conjugate (Scheme 2, pathway C), which led to the formation of a Pt-folate 
conjugate lacking the pterin fragment (10), which was subsequently transformed into the 
expected photoproducts (6-8) due to photoreduction of the intact Pt(IV) complex. A minor 
non-photoactivatable Pt-folate conjugate lacking the pterin ring (11) was also identified in the 
crude mixture of photolysis products. Similar results were obtained upon irradiation with 
green light (Fig. S6, ESI†).  
 
Fig. 3 Reversed-phase HPLC-MS analysis of the photoactivation of Pt-folate conjugate 3 in 




Scheme 2. Photoactivation pathways for Pt-folate conjugate 3. 
 
Since photodecomposition of folic acid into p-aminobenzoyl-L-glutamic acid and 6-
formylpterin or 6-carboxypterin derivatives has been reported to occur upon irradiation with 
UV light,21 we investigated the photostability of folate derivative 4 under the irradiation 
conditions. As shown in Fig S7 (ESI†), 4 was stable both after irradiation with blue (2 h, 37 
oC) or green (1 h, 37 oC) light, which suggested the involvement of the Pt(IV) complex or its 
photoproducts in the photodegradation of folic acid. In order to confirm this hypothesis, we 
irradiated an equimolar mixture of 4 and complex 1. Very interestingly, HPLC-MS analysis 
(Fig. S8, ESI†) revealed the presence of the p-aminobenzoate derivative 12 and 6-
formylpterin 9 together with several Pt(II) photoproducts, with 6 and 13 being the main 
platinum species (Scheme 3). Further evidence of the photodecomposition of folic acid 
mediated by complex 1 was obtained by 1H NMR spectroscopy. As shown in Fig. S9 (ESI†), 
green light irradiation of an equimolar mixture of folic acid and Pt(IV) complex 1 in DMSO-
d6/D2O 8:2 (v/v) for 2 h at 37 oC led to the disappearance of the 1H NMR peaks for the CH2 
group linking p-aminobenzoate and pterin moieties. In addition, the appearance of peaks 
around 9.9 ppm together with a shift of proton 7 of the pterin heterocycle to lower field (9.02 
ppm vs. 8.61 ppm in free folic acid) confirmed the photodecomposition of folic acid in 6-
formylpterin derivatives and in the p-aminobenzoyl-L-glutamic acid.  
Overall, these experiments demonstrated the participation of the trans-diazido Pt(IV) 
complex on the photodegradation of folic acid, even when both compounds were not 
covalently attached. Oxidative attack of azidyl radicals produced by photodecomposition of 
complex 1 on the pterin heterocycle might trigger the cleavage of folic acid in a similar 
fashion as occurs with tryptophan amino acid and tryptophan-containing peptides.22 Such 
unexpected results might be biologically relevant since pterin photoproducts generate 
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reactive oxygen species (ROS)21c and, consequently, the mechanism of action of Pt-folate 
conjugate 3 could involve photodynamic therapy (PDT) besides PACT. 
 
Scheme 3. Photoactivation of an equimolar mixture of complex 1 and folate derivative 4. 
 
Having established the photoactivation properties of the Pt-folate conjugate 3, we focused on 
investigating photocytotoxicity towards MCF-7 breast cancer cell line. Since conventional cell 
culture media contains a folic acid concentration much higher (ca. 2.2 M) than that typically 
found in blood plasma (ca 4.5-50 nM),23 photocytotoxicity studies were carried out in folic 
acid-free DMEM to assess the effect of the folate vector on delivery of the metallodrug into 
MCF-7 cancer cells. The photocytotoxicity of conjugate 3 and of the parent Pt(IV) pro-drug 
(1) was determined upon irradiation with blue visible LED light (irr = 465 nm, 4.8 mW cm-2). 
The dose-dependent inhibition of cell viability for the compounds towards MCF-7 cells, which 
was determined by the sulforhodamine B (SRB) colorimetric assay, and their phototoxic 
indices are summarized in Table 1. First, it is worth noting that both compounds are found 
non-toxic towards the MCF-7 cancer cell line in the dark with IC50 values >100 μM. However, 
irradiation with blue light led to a significant enhancement of the cytotoxicity in both cases, 
with the photocytotoxicity of Pt-folate conjugate (IC50 = 14.4 μM) being greater than that of 
the parent Pt(IV) complex (IC50 = 32.4 μM) with photocytotoxicity indices (PI) of >6.9 and 
>3.0, respectively. Overall, these results indicate that the photocytotoxicity of the trans-
diazido Pt(IV) pro-drug towards MCF-7 breast cancer cells can be significantly enhanced 




Table 1. IC50 values and photocytotoxicity indices (PI) for Pt-folate conjugate 3 and the 
parent Pt(IV) complex 1 in MCF-7 breast cancer cells after 1 h incubation, 1 h irradiation 
(blue 465 nm, 4.8 mW cm-2) and 24 h recovery. 
 
  IC50 (µM)
a 
Pt-folate conjugate 3 
Dark > 100 
Irrad. 14.4 ± 1.0 
PI > 6.9 
Pt(IV) Complex 1 
Dark > 100 
Irrad. 32.4 ± 3.3 
PI > 3.0 
a Data are from three independent experiments 
 
Cellular accumulation of metal-based anticancer drugs usually plays an important role in their 
antiproliferative activity, especially when conjugated to targeting ligands whose receptors are 
overexpressed on the cell surface.24 For this reason, we investigated platinum accumulation 
by MCF-7 cancer cells after exposure to 10 μM solutions of Pt-folate conjugate 3 and 
complex 1 for 1 h in the dark at 37 oC. Inductively-coupled plasma mass spectrometry (ICP-
MS) was used to quantify the intracellular level of Pt in both cases (Table 2). Very 
interestingly, the cellular accumulation of Pt from conjugate 3 (5.8 ng per 106 cells) in MCF-7 
cell line was about 9x higher than that of the parent complex 1 (0.67 ng per 106 cells), which 
is in good agreement with the higher photocytotoxicity of the conjugate. In order to obtain 
more insight into the participation of folate receptor in the cellular uptake of the conjugate, Pt 
accumulation studies were repeated at low temperature. As shown in Table 2, the incubation 
of MCF-7 cells with conjugate 3 at 4 oC led to a reduction in the Pt accumulation (ca. 33 %). 
Competitive studies with folic acid further confirmed the involvement of folate receptor in the 
internalization of the Pt-folate conjugate in breast cancer cells, which have been reported to 
exhibit medium folate receptor expression on their surface.25 Indeed, pre-treatment of MCF-7 
cells with folic acid (100 mol equiv.) led to a slight reduction in Pt accumulation from 3. 
Overall, these results suggest the participation of the folate receptor in the cellular uptake of 
Pt-folate conjugate in MCF-7 cells and that it enters the cells through an energy-dependent 







Table 2. Cell accumulation of Pt (ng per 106 cells) in MCF-7 cancer cells after exposure to 
Pt-folate conjugate 3 and the parent Pt(IV) complex 1 (10 μM, 1 h, in the dark). 
Compound Temperature Platinum accumulation  
(ng per 106 cells)a 
Pt-folate conjugate 3 
4°C 3.9 ± 0.6 
37°C 5.8 ± 0.4 *** 
Pt-folate+100 eq folate 37°C 5.5 ± 0.7 ** 
Complex 1 37°C 0.67 ± 0.12* 
a All data were determined from triplicate samples and compared with values obtained for 
untreated cells using a two-tail t-test with unequal variances. *p < 0.05, **p < 0.01, ***p < 
0.005. 
 
In summary, we have synthesized and characterized a novel conjugate between a 
photoactivatable trans-diazido Pt(IV) pro-drug and folic acid with the aim of generating folate-
receptor targeted anticancer metallodrugs operating with a novel mechanism of action. 
Photoactivation of the Pt-folate conjugate with visible light confirmed the generation of 
cytotoxic Pt(II) species capable of binding to guanine nucleobases. In addition, 
photoreduction of the Pt(IV) complex was accompanied by the photodecomposition of the 
folate vector into a p-aminobenzoate-containing fragment and several pterin derivatives, 
including 6-formylpterin, a process that might be triggered by azidyl radicals produced during 
the photoactivation of the Pt(IV) pro-drug. Besides exhibiting high dark stability under 
physiological-like relevant conditions, the Pt-folate conjugate was found ca. 2x photocytotoxic 
towards MCF-7 breast cancer cell line than its parent Pt(IV) complex. The higher 
photocytotoxicity of the conjugate (PI >6.9) compared with the parent Pt(IV) pro-drug (PI 
>3.0) might be attributable both to a higher cellular accumulation and to the generation of 
several cytotoxic species, including Pt(II) photoproducts and pterin derivatives which are 
known to generate ROS. This work suggests for the first time that folic acid conjugation to 
photoactivatable metallodrugs could be exploited to improve selectivity towards cancer cells 
overexpressing folate receptor as well as to attack them by combining PACT and PDT. Work 
is in progress to investigate the contribution of photoreleased pterin derivatives to the 
photocytotoxicity of such Pt-folate conjugates.  
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